The Approval
In a landmark regulatory decision, the FDA granted De Novo classification to Paige AI's PathAssist system for autonomous detection of prostate cancer in biopsy slides. This marks the first time an AI system has been authorized to make diagnostic decisions independently in oncology, without requiring a pathologist to review each result.
How It Works
PathAssist uses a vision transformer model trained on over 2 million annotated pathology slides from 30+ institutions globally. The system:
- Analyzes whole-slide digital pathology images at 40x magnification
- Identifies cancerous regions with 99.6% sensitivity and 98.2% specificity
- Classifies Gleason grades for prostate cancer staging
- Flags ambiguous cases for human pathologist review
Clinical Impact
The approval addresses a critical bottleneck: the global shortage of pathologists. The WHO estimates a deficit of over 500,000 pathologists worldwide, with wait times for biopsy results stretching to weeks in many regions. PathAssist can process a slide in under 90 seconds.
This isn't about replacing pathologists — it's about ensuring every patient gets a timely, accurate diagnosis regardless of where they live. — Dr. Leo Grady, CEO of Paige AI
Industry Response
The decision has sparked debate about the pace of autonomous AI in medicine. The American College of Pathologists issued a cautious endorsement, while patient advocacy groups praised the potential to reduce diagnostic delays. Shares of digital pathology companies surged 15-20% on the news.